HAEM5:Myelodysplastic neoplasm with biallelic TP53 inactivation: Difference between revisions
| [checked revision] | [checked revision] |
Updated to reflect new somatic format. |
No edit summary |
||
| Line 46: | Line 46: | ||
!Clinical Relevance Details/Other Notes | !Clinical Relevance Details/Other Notes | ||
|- | |- | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
|} | |} | ||
| Line 302: | Line 302: | ||
*A complex karyotype (at least three distinct abnormalities excluding loss of Y) and/or 17p deletion detected by analysis of banded chromosomes, in the context of one detected ''TP53'' variant, can be considered evidence of biallelic inactivation | *A complex karyotype (at least three distinct abnormalities excluding loss of Y) and/or 17p deletion detected by analysis of banded chromosomes, in the context of one detected ''TP53'' variant, can be considered evidence of biallelic inactivation | ||
*If myeloid blasts account for 10-19% of cellularity in blood or bone marrow then a diagnosis of MDS/AML with mutated ''TP53'' is applied (for which only a single ''TP53'' mutation with VAF ≥10% is required for diagnosis) | *If myeloid blasts account for 10-19% of cellularity in blood or bone marrow then a diagnosis of MDS/AML with mutated ''TP53'' is applied (for which only a single ''TP53'' mutation with VAF ≥10% is required for diagnosis) | ||
==Links== | |||
Links | |||
Put your text placeholder here (use "Link" icon at top of page) | Put your text placeholder here (use "Link" icon at top of page) | ||
==References== | ==References== | ||